“Fibroblast” pharmacotherapy - Advancing the next generation of therapeutics for clinical cardiology

- All three compartments of RAS (circulating, tissue and intracellular) are critical in the pathogenesis of heart failure.
- Fibroblasts are active, not passive, endocrine regulators of ECM remodeling that are regulated by RAS.
- Fibroblasts synthesize chymase, an essential modulator of RAS activity, which affects modulating cardiac ECM.
- Only 2 of 8 drug classes are widely used to manage RAS; future therapeutics are targeting chymase as a key regulator of RAS.